George B. Rathmann, a chemist who led and helped transform Amgen into one of the world's largest biotechnology firms in the 1980s and who later co-founded the company that manufactured the anti-impotence drug Cialis, died Sunday at his home in Palo Alto, Calif. He was 84.
He had complications from kidney disease, said his son James Rathmann.
Forbes magazine once called George Rathmann "the Bill Gates of biotechnology" for his success in turning scientific research into an immensely profitable venture as chief executive and president of California-based Amgen from 1980 to 1990.
He was often described as a rare scientist who also possessed a sharp business mind. At Amgen, he oversaw the development of Epogen, a drug that stimulates red blood cell production and is used to energize patients with chronic anemia.
After leaving Amgen, Mr. Rathmann helped found Icos, a biotechnology firm in Bothell, Wash. He personally secured a crucial investment from Mr. Gates, the Microsoft co-founder and billionaire. Icos' signature product was Cialis, a vasodilator that induces erections. The pharmaceutical giant Eli Lilly bought out Icos in the mid-2000s.
Epogen and Cialis have improved millions of lives and have reaped billions of dollars in sales.
George Blatz Rathmann was born Dec. 25, 1927, in Milwaukee. He was a 1948 chemistry graduate of Northwestern University in Evanston, Ill. In 1950, he received a master's degree in physical chemistry from Princeton University, where he also earned a doctorate in 1952. He joined 3M, where he worked on X-ray film and other projects.
One day at a 3M lab, Mr. Rathmann and some other researchers were experimenting with a new compound when one of the scientists spilled some of the mixture on her shoe. While attempting to wash the shoe, the group realized the water was beading off the top.
Discovering the mixture's unique water-repelling qualities, they perfected it into Scotchgard.
Mr. Rathmann was serving as vice president of research and development for Illinois-based Abbott Laboratories when he was recruited to Amgen in 1980 by a group of venture capitalists.




Comments
Welcome to Post-Gazette subscriber-only commenting community. Please review our community guidelines.